GLUT2 inhibition is desirable for patients with fructose-induced metabolic disorders, but it may lead to insulin insensitivity (Ferraris et al., 2018), suggesting that specific inhibition of GLUT2 is necessary. Here, SLC2A2 is linked to metabolic disease.